Cardiology

A group of 9 experts in heart failure, ranging from leading trialists to early career clinicians, provide perspective on what they see as the biggest news in heart failure from 2023.

Ahmad Masri, MD, MS, discusses long-term data from the open-label extension period of the phase 2 AG10-201 trial examining acoramidis in patients with ATTR-CM.

Ahmad Masri, MD, MS, offers perspective om the study design of the ACACIA-HCM trial and the unmet need within nonobstructive hypertrophic cardiomyopathy.

Ankeet Bhatt, MD, MBA provides additional perspective on a recent study examining the cost-effectiveness and health impact of sacubitril/valsartan use at different thresholds of ejection fraction.

Use of antiviral therapy was linked to a decreased risk of multiple cardiovascular outcomes and mortality compared to patients not using antiviral therapy.

Ankeet Bhatt, MD, MBA, offers perspective into the results of a recent analysis of the GWTG-HF registry at HFSA 2023.

Data from a phase 1b trial presented at HFSA 2023 detail the effects of JK07, an investigational agent from Salubris Biotherapeutics, in patients with heart failure with reduced ejection fraction.

On the floor at HFSA 2023, Muthiah Vaduganathan, MD, MPH, provides his perspective on the latest IV iron supplementation guidelines from the European Society of Cardiology.

A study presented at HFSA 2023 offers clinicians an overview of the influence of socioeconomic status on access to implantable hemodynamic monitors using the National Inpatient Sample.

Announced on October 9, the decision to issue a CRL is based on the FDA's belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established.

Prespecified analysis of STEP-HFpEF trial shows semaglutide benefits consistent across ejection fraction spectrum, offering potential HFpEF management.

Hosts are joined by Marat Fudim, MD, MHS, of Duke, to discuss the REBALANCE-HF trial, which examined endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction.

DELTA-HF trial: Device-based thoracic duct decompression with the eLym system could prove beneficial in acute decompensated heart failure patients.

The REBALANCE-HF trial at HFSA 2023 reveals that right greater splanchnic nerve ablation was well-tolerated and safe in patients with HFpEF, with additional analysis shedding light on the proportion of responders to the procedure.

Anand Shah, MD, MBA, provides insights into a study he led examining the impact of out-of-pocket costs and insurance type on uptake of GDMT in patients with heart failure with reduced ejection fraction.

A propensity score-matched analysis of data suggests use of spironolactone could reduce the 3-year risk of developing Alzheimer disease or dementia among patients with heart failure with reduced ejection fraction.

José López, MD, discusses the results of a study he led examining contemporary trends in racial disparities as it pertains to LVAD utilization in patients with heart failure with reduced ejection fraction.

Lauren Eyadiel, MMS, PA-C, offers insight into a presentation from HFSA 2023 examining strategies for overcoming financial barriers to GDMT optimization in heart failure.

Muthiah Vaduganathan, MD, MPH, offers insight and perspective into a new annual report from the Heart Failure Society of America outlining trends in epidemiology and outcomes in heart failure.

In our September 2023 cardiology month in review, the editorial team of HCPLive Cardiology highlights a trio of regulatory decision from the FDA and a group of 5 different articles spotlighting data from phase 2 or phase 3 trials.

Stephen Greene, MD, discusses trials, data, and themes to look for at the HFSA 2023 meeting.

The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.

Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.

A new initiative from the HFSA highlights key findings on heart failure prevalence, risk, mortality and hospitalization rates in the United States.

An analysis of more than 1 million men found higher blood pressure in late adolescence was associated with an increased risk for major cardiovascular events in later life.

Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.

Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.

Granted a PDUFA date in March 2024, if approved, sotatercept would be a first-in-class medication to address the rare and progressive disease.

Andrew Wang, MD; James Januzzi, MD; Michelle M. Kittleson, MD, PhD; and Milind Desai, MD, MBA, share a look into the future of oHCM treatment.

Michelle M. Kittleson, MD, PhD, comments on remaining unanswered questions regarding CMIs in treatment of oHCM, highlighting disease modification.